Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-α priming

Cancer Letters

Volumn 293, Issue 2, 2010, Pages 198-206

  de Vries van Leeuwen, Ingrid J ^a   Kortekaas Thijssen, Chantal ^a   Nzigou Mandouckou, Jean A ^a   Kas, Sjors ^a   Evidente, Antonio ^b   de Boer, Albertus H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

14 3 3; Apoptosis; Fusicoccin; Interferon ; OVCAR3; TRAIL

Indexed keywords

COTYLENIN A; CYTOKINE; FUSICOCCIN; FUSICOCCIN A; HLA DR4 ANTIGEN; MYCOTOXIN; OPHIOBOLIN A; OPHIOBOLIN I; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GLYCOSIDE; OPHIOBOLINS; SESTERTERPENE; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TUMOR CELL LINE; UMBILICAL VEIN; CELL LINE; DRUG EFFECT; METABOLISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; GLYCOSIDES; HUMANS; INTERFERON-ALPHA; SESTERTERPENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77952504491     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.009     Document Type: Article

References (42)

1. Mita M., Mita A., Tolcher A. Apoptosis: mechanisms and implications for cancer therapeutics. Targeted Oncology 2006, 1:197-214.
2. Desagher S., Martinou J.-C. Mitochondria as the central control point of apoptosis. Trends in Cell Biology 2000, 10:369-377.
3. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer 2008, 8:782-798.
4. Elrod H.A., Sun S.-Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biology & Therapy 2008, 7:163-173.
5. Wadler S., Schwartz E.L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Research 1990, 50:3473-3486.
6. Platanias L.C. Mechanisms of type-I- and type-II-interferon mediated signalling. Nature Reviews Immunology 2005, 5:375-386.
7. Chawla-Sarkar M., Lindner D.J., Liu Y.-F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, V8:237-249.
8. Ferrantini M., Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Seminars in Cancer Biology 2000, 10:145-157.
9. Schneider B., Fukunaga A., Murry D., Yoder C., Fife K., Foster A., Rosenberg L., Kelich S., Li L., Sweeney C. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors. Cancer Chemotherapy and Pharmacology 2007, 59:261-268.
10. Son M.J., Song H.S., Kim M.H., Kim J.T., Kang C.-M., Jeon J.W., Park S.-Y., Kim Y.-J., Groves M.D., Park K., Kim J.-H., Nam D.-H. Synergistic effect and condition of pegylated interferon with paclitaxel on glioblastoma. International Journal of Oncology 2006, 28:1385-1392.
11. Lesinski G.B., Raig E.T., Guenterberg K., Brown L., Go M.R., Shah N.N., Lewis A., Quimper M., Hade E., Young G., Chaudhury A.R., Ladner K.J., Guttridge D.C., Bouchard P., Carson W.E. IFN-{alpha} and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Research 2008, 68:8351-8360.
12. Honma Y., Ishii Y., Yamamoto-Yamaguchi Y., Sassa T., Asahi K.-I. Cotylenin A, a differentiation-inducing agent, and IFN-{alpha} cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice. Cancer Research 2003, 63:3659-3666.
13. Ballio A., Chain E.B., De Leo P., Erlanger B.F., Mauri M., Tonolo A. Fusicoccin: a new wilting toxin produced by Fusicoccum amygdali Del. Nature 1964, 203. 297-297.
14. Muromtsev G., Voblikova V., Kobrina N., Koreneva V., Krasnopolskaya L., Sadovskaya V. Occurrence of fusicoccanes in plants and fungi. Journal of Plant Growth Regulation 1994, 13:39-49.
15. Korthout H., de Boer A.H. A fusicoccin binding protein belongs to the family of 14-3-3 brain protein homologs. Plant Cell 1994, 6:1681-1692.
16. Bunney T.D., De Boer A.H., Levin M. Fusicoccin signaling reveals 14-3-3 protein function as a novel step in left-right patterning during amphibian embryogenesis. Development 2003, 130:4847-4858.
17. Leung P.C., Taylor W.A., Wang J.H., Tipton C.L. Ophiobolin A. A natural product inhibitor of calmodulin. Journal of Biological Chemistry 1984, 259:2742-2747.
18. Au T.K., Chick W.S.H., Leung P.C. The biology of ophiobolins. Life Sciences 2000, 67:733-742.
19. Kong Au T., Chow Leung P. Identification of the binding and inhibition sites in the calmodulin molecule for ophiobolin a by site-directed mutagenesis. Plant Physiology 1998, 118:965-973.
20. Leung P.C., Graves L.M., Tipton C.L. Characterization of the interaction of ophiobolin A and calmodulin. International Journal of Biochemistry 1988, 20:1351-1359.
21. Wurtele M., Jelich-Ottmann C., Wittinghofer A., Oecking C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO Journal 2003, 22:987-994.
22. Aitken A. 14-3-3 Proteins: a historic overview. Seminars in Cancer Biology 2006, 16:162-172.
23. Hermeking H. The 14-3-3 cancer connection. Nature Reviews Cancer 2003, 3:931-943.
24. Wu M., Coblitz B., Shikano S., Long S., Cockrell L.M., Fu H., Li M. SWTY - a general peptide probe for homogeneous solution binding assay of 14-3-3 proteins. Analytical Biochemistry 2006, 349:186-196.
25. Muller P., Janovjak H., Miserez A., Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 2002, 32:1372-1379.
26. 2+ channels by transient receptor potential vanilloid type 1 stimulation with olvanil in primary sensory neurons. Neuroscience 2006, 141:407-419.
27. Au T.K., Chick W.S.H., Leung P.C. Initial kinetics of the inactivation of calmodulin by the fungal toxin ophiobolin A. The International Journal of Biochemistry & Cell Biology 2000, 32:1173-1182.
28. Asahi K.-I., Honma Y., Hazeki K., Sassa T., Kubohara Y., Sakurai A., Takahashi N. Cotylenin A, a plant-growth regulator, induces the differentiation in murine and human myeloid leukemia cells. Biochemical and Biophysical Research Communications 1997, 238:758-763.
29. Honma Y., Kasukabe T., Yamori T., Kato N., Sassa T. Antitumor effect of cotylenin A plus interferon-[alpha]: possible therapeutic agents against ovary carcinoma. Gynecologic Oncology 2005, 99:680-688.
30. Shen X., Krasnoff S.B., Lu S.-W., Dunbar C.D., O'Neal J., Turgeon B.G., Yoder O.C., Gibson D.M., Hamann M.T. Characterization of 6-epi-3-anhydroophiobolin B from Cochliobolus heterostrophus. Journal of Natural Products 1999, 62:895-897.
31. Fernandez-Aparicio M., Andolfi A., Cimmino A., Rubiales D., Evidente A. Stimulation of seed germination of Orobanche species by ophiobolin A and fusicoccin derivatives. Journal of Agricultural and Food Chemistry 2008, 56:8343-8347.
32. Nejidat A. Effect of ophiobolin-A on stomatal movement - role of calmodulin. Plant and Cell Physiology 1987, 28:455-460.
33. Evidente A., Andolfi A., Cimmino A., Vurro M., Fracchiolla M., Charudattan R. Herbicidal potential of ophiobolins produced by Drechslera gigantea. Journal of Agricultural and Food Chemistry 2006, 54:1779-1783.
34. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Research 2005, 7:R1097-R1110.
35. Ottmann C., Weyand M., Sassa T., Inoue T., Kato N., Wittinghofer A., Oecking C. A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A. Journal of Molecular Biology 2009, 386:913-919.
36. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'en P., Xu X.N., Jin B.Q., Pezzella F., Screaton G.R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Research 2005, 15:430-438.
37. Zhang X.D., Franco A.V., Nguyen T., Gray C.P., Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. Journal of Immunology 2000, 164:3961-3970.
38. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J.S., Cohen G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Research 2005, 65:11265-11270.
39. van der Sloot A.M., Tur V., Szegezdi E., Mullally M.M., Cool R.H., Samali A., Serrano L., Quax W.J. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proceedings of the National Academy of Sciences 2006, 103:8634-8639.
40. Abdollahi T., Robertson N.M., Abdollahi A., Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Research 2003, 63:4521-4526.
41. Bin L., Thorburn J., Thomas L.R., Clark P.E., Humphreys R., Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. Journal of Biological Chemistry 2007, 282:28189-28194.
42. Yanase N., Hata K., Shimo K., Hayashida M., Evers B.M., Mizuguchi J. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Experimental Cell Research 2005, 310:10-21.